VC/PE/M&A. Healthcare Weekly(2017.12.11)

 Tue Dec 12 11:00:29 CST 2017 A- A+

作者:克莱尔

本期内容概览

FXR治疗锋芒初现!加州初创公司Metacrine剑指非酒精性脂肪肝。

大鳄吃下领头羊:史赛克6.62亿美元收购Entellus Medical!

奇货可居?移植器械研发公司Exactech被TPG收购交易再加码。

私募融资 & IPO

1.FXR治疗锋芒初现!加州初创公司Metacrine剑指非酒精性脂肪肝

概要:近期,位于美国加州圣迭戈的脂肪肝和糖尿病生物制药公司 Metacrine宣布获得2200万美元的B轮融资。除了此前的投资方ARCH,Polaris,venBio 和 Alexandria Venture Investments 继续注资之外,New Enterprise Associates加入此轮并领投。至此,这家成立两年的公司已获得总计6000万美元投资。根据研究,未来十年,非酒精性脂肪肝(Non Alcoholic Fatty Liver Disease,简称NASH)的治疗市场将达到百亿美元规模,市场上已经有十余家生物制药公司从潜伏期临床试验到三期试验布局并研究NASH治疗的相关作用机理(MOA)。Metacrine虽然仍处于初创阶段,但是却有望发展处市场上最优秀的FXR(一种多靶点的核受体)项目(尽管仍需在人体试验上先产生结果),并正在一些等大公司已经开拓的FXR道路上前进,如吉列德(Gilead)的GS-9674项目等。Metacrine公司的总裁兼CEO Ken Song表示:“非酒精性脂肪肝是市场上迄今医疗需求最没能被满足的疾病之一。我们相信,FXR是治疗该疾病的很有潜力的靶点,我们也有信心用相关分子弥合医疗需求和已有资源之间的鸿沟。除了非酒精性脂肪肝以外,我们也准备把FXR用于其他疾病的临床治疗。”

相关报道:

Metabolic biotech Metacrine gains $22M for NASH tests

Dec 7, 2017

You know the drill: Potential tens of billions in market share from next decade; about a dozen biopharma from phase preclinical to 3 are at work using several different MOAs; caution from some on diagnostics and targets (i.e., liver fat and fibrosis) alongside some mixed results, and so on. The San Diego biotech, which is very early-stage, is hoping to have the best-in-class FXR program ( though it will need to prove that in human testing ahead ), and is following the route set by some others, such as Gilead and its phase 2 FXR agonist GS-9674. Metacrine now hopes to join the ranks of those in the NASH race with a $22 million series B by new investor New Enterprise Associates along with existing investors ARCH, Polaris, venBio, and Alexandria Venture Investments. Since starting out two years ago with a focus on diabetes and NASH, the biotech has received $60 million in funding.

The company says that over the course of the past year it has been pushing on with its lead asset, MET409, an oral non-bile acid FXR agonist, into late stage IND-enabling studies: the first tests in humans should come in the middle of next year. Metacrine says MET409 has “been purposefully designed to have a differentiated profile to position it as best-in-class for efficacy and safety.” The company is also targeting other forms of liver inflammation and fibrosis, as well as using the cash boost toward an FGF1 program, a first-in-class insulin sensitizer, which is in collab with diabetes major Novo Nordisk. Ken Song, M.D., president and CEO of Metacrine, said: “NASH represents one of the largest unmet medical needs in medicine today. We believe FXR is a compelling NASH target and that our program addresses the gaps in delivering a best-in-class molecule. In addition to NASH, we have outlined a strategy to pursue FXR in other clinical indications.”

Source: FierceBiotech

https://www.fiercebiotech.com/biotech/metabolic-biotech-metacrine-gains-22m-for-nash-tests

并 购

1. 大鳄吃下领头羊:史赛克6.62亿美元收购Entellus Medical!

概要:成立于2006年、位于美国明尼苏达州普利茅斯的Entellus Medical近日宣布被医疗器械大鳄史赛克(Stryker)以6.62亿美元收购。该公司专攻微创领域气球器械的研发,其旗舰产品为治疗鼻窦闭塞的Xpress。今年早些时候,这家公司斥资8100万美元收购了Spirox及其可吸收鼻假体植入装置Latera。史赛克医疗手术及神经科技业务总裁Timothy Scannell表示,Entellus是ENT领域的领头羊,为市场提供了全面的ENT产品,使得医疗从业者能够更高效和舒适地开展相关手术。

相关报道:

Stryker pledges $662m cash for Entellus Medical

Dec 7, 2017

Entellus Medical (NSDQ:ENTL) said today that it struck a deal to be acquired by Stryker (NYSE:SYK) for $662 million in cash. Plymouth, Minn.-based Entellus, founded in 2006, makes a family of minimally invasive balloon device products, including its flagship Xpress device, that are designed to treat blocked sinuses. Earlier this year it closed the $81 million buyout of Spirox and its Latera absorbable nasal implant.The company’s shareholder must still approve the $24-per-share deal.

“Entellus is a leader in the ENT segment and offers a comprehensive portfolio of products that enable physicians to conveniently and comfortably perform a broad range of ENT procedures,” added Stryker medsurg & neurotech president Timothy Scannell.

Source: MassDevice

http://www.massdevice.com/stryker-pledges-662m-cash-entellus-medical/

2.奇货可居?移植器械研发公司Exactech被TPG收购交易再加码

概要:市场领先的医疗器械研发公司Exactech近日宣布修订于今年10月23日与TPG资本及其部分附属机构达成的收购协议。Exactech专攻整形手术中手足及大关节的植入装置的研发。根据新的协议,公司的每股股价将从此前达成收购协议后的42美元跃升17.3%至49.25美元。TPG同时将其股权投资额增至7.37亿美元,以期完成交易。

相关报道:

Exactech and TPG Capital Announce Amended Merger Agreement Providing for Increase in Merger Consideration to $49.25 per share

Dec 4, 2017

Exactech, Inc. (Nasdaq:EXAC), a leading developer and producer of orthopedic implant devices andsurgical instrumentation for extremities and large joints, announced today that it has entered into an amendment to its merger agreement with TPG Capital andcertain of its affiliates which was previously announced on October 23, 2017.Pursuant to the amended merger agreement, the Company’s common stock outstanding immediately prior to the effective time of the merger (other thancertain shares held by the Company’s founders and certain management shareholders) will be converted into the right to receive $49.25 per share incash. This represents an increase of approximately 17.3% over the $42.00 of per share merger consideration previously agreed to by Exactech and TPG Capital.TPG Capital has also increased its equity financing commitment to $737 millionfor purposes of consummating the merger. Pursuant to a rolloverand voting support agreement entered into at the time of the amended mergeragreement, the Company’s founders, CEO and certain other managementshareholders have agreed with TPG to exchange a portion of their shares in thetransaction, representing approximately 18.8% of the Company’s outstanding common stock, for new equity securities in the post-closing ownership of the Company at a valuation equal to or less than $49.25 per share. Such founding and management shareholders have previously agreed to vote all of their sharesfor the approval of the amended merger agreement.

Source: Business Wire

https://www.businesswire.com/news/home/20171204005278/en/Exactech-TPG-Capital-Announce-Amended-Merger-Agreement

以上,难免有疏漏或不正确之处,请多多指出,并在文下留言处留言,谢谢!

*声明:本文由入驻新浪医药新闻作者撰写,观点仅代表作者本人,不代表新浪医药新闻立场。
收藏
扫描二维码,关注新浪医药(sinayiyao)公众号
360°纵览医药全局,365天放送新闻时事医药资讯轻松一览
精彩不容错过。
文章评论
肖恩大侠 华盖医疗基金董事总经理,北京。 毕业于北京大学工学院医学院(医学硕士)、北京大学法学院(法学硕士)。资浅PE从业人士。躬耕于太湖,游学至未名,当过医生,学过法律,改行至风险投资,喜好读书写作,经史文集,现代科技都甚喜欢,总是怀着理想,万一,实现了呢?欢迎交流医疗、文化、消费,欢迎交流一级市场、二级市场,欢迎交流国内及海外并购。 邮箱:shawn.shiqq.com
+订阅
印象笔记
有道云笔记
微信
二维码
意见反馈